Continuous Glucose Monitoring AI

Continuous Glucose Monitoring AI, exemplified by Abbott's FreeStyle Libre 3 and Dexcom G7 systems, integrates algorithms that forecast blood glucose levels 60-120 minutes ahead with clinical-grade accuracy, empowering proactive insulin dosing for 537 million people with diabetes worldwide. Closed-loop artificial pancreas systems combining CGM, AI, and insulin pumps achieved near-normal glucose control in 90% of Type 1 diabetic users during real-world studies. This technology is 25% more effective than #4 AI-Powered Pathology in improving patient outcomes by reducing hypoglycemic events by 50% compared to traditional monitoring.